Research Topic

Disorders Related to PI3K Hyper-activation

About this Research Topic

The tuning of PI3Kdelta kinase is a crucial process in immune cell biology. Impaired PI3K signaling is involved in several primary immunodeficiencies and in hematologic malignancies. Treatments targeting the PI3K kinase or the PI3K-AKT-mTOR signaling have been proposed in various immune disorders, especially in the presence of nonproliferation.

The Research Topic will focus on biological regulation of the PI3K-AKT-mTOR in healthy and diseased immune functions. The collection will address clinical and pathological aspects of primary immunodeficiencies, like Activated PI3Kdelta kinase (APDS) and Autoimmune Lymphoproliferative Syndrome (ALPS), characterized by dysregulated PI3K signaling. The collection will also focus on the pathogenesis of autoimmunity and inflammation associated with PI3K dysregulation. Moreover, the role of PI3K in hematologic malignancies and viral infections, such as EBV, can also be discussed. Finally, therapeutic approaches targeting the PI3K-AKP-mTOR pathway will be considered, as well as laboratory and clinical investigation useful in the follow-up of the treated patients.


Keywords: PI3K signaling, PI3Kdelta kinase, Pi3k Hyper-activation, PI3K-AKT-mTOR, immunodeficiencies, hematologic malignancies


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

The tuning of PI3Kdelta kinase is a crucial process in immune cell biology. Impaired PI3K signaling is involved in several primary immunodeficiencies and in hematologic malignancies. Treatments targeting the PI3K kinase or the PI3K-AKT-mTOR signaling have been proposed in various immune disorders, especially in the presence of nonproliferation.

The Research Topic will focus on biological regulation of the PI3K-AKT-mTOR in healthy and diseased immune functions. The collection will address clinical and pathological aspects of primary immunodeficiencies, like Activated PI3Kdelta kinase (APDS) and Autoimmune Lymphoproliferative Syndrome (ALPS), characterized by dysregulated PI3K signaling. The collection will also focus on the pathogenesis of autoimmunity and inflammation associated with PI3K dysregulation. Moreover, the role of PI3K in hematologic malignancies and viral infections, such as EBV, can also be discussed. Finally, therapeutic approaches targeting the PI3K-AKP-mTOR pathway will be considered, as well as laboratory and clinical investigation useful in the follow-up of the treated patients.


Keywords: PI3K signaling, PI3Kdelta kinase, Pi3k Hyper-activation, PI3K-AKT-mTOR, immunodeficiencies, hematologic malignancies


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

30 April 2021 Manuscript
31 May 2021 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

30 April 2021 Manuscript
31 May 2021 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..